- Home
- AGIO vs BWLP Comparison
AGIO vs BWLP Comparison
Compare AGIO & BWLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGIO | BWLP |
|---|---|---|
| Founded | 2007 | 1935 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | AGIO | BWLP |
|---|---|---|
| Price | $28.92 | $12.60 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $32.13 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 432.4K |
| Earning Date | 02-12-2026 | 12-02-2025 |
| Dividend Yield | N/A | ★ 10.46% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.14 |
| Revenue | $44,791,000.00 | ★ $3,693,482,000.00 |
| Revenue This Year | $28.75 | N/A |
| Revenue Next Year | $139.45 | $4.24 |
| P/E Ratio | ★ N/A | $11.17 |
| Revenue Growth | ★ 36.26 | 2.54 |
| 52 Week Low | $22.24 | $7.86 |
| 52 Week High | $46.00 | $16.60 |
Technical Indicators
Market Signals| Indicator | AGIO | BWLP |
|---|---|---|
| Relative Strength Index (RSI) | 50.24 | 51.38 |
| Support Level | $24.16 | $12.31 |
| Resistance Level | $27.95 | $12.65 |
| Average True Range (ATR) | 1.20 | 0.23 |
| MACD | 0.50 | 0.07 |
| Stochastic Oscillator | 82.82 | 92.42 |
Price Performance
Historical ComparisonAbout AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About BWLP BW LPG Limited
BW LPG Ltd is an LPG shipping. It uses pioneering technology to power its vessels with cleaner-burning liquefied petroleum gas (LPG) and invest in R&D to take towards a zero-carbon future. The company is organized into two main segments: The shipping segment and the product services segment which buy and sell liquid petroleum gas and deliver it to customers. It generates the majority of its revenue from the shipping segment.